tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

KROS Stock Latest News

Strategic Opportunities and Partnerships Highlight Keros Therapeutics’ Potential: A Buy Recommendation by Jason Zemansky
RatingsStrategic Opportunities and Partnerships Highlight Keros Therapeutics’ Potential: A Buy Recommendation by Jason Zemansky
17d ago
KROS
Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz
PremiumThe Fly
Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz
18d ago
F
X
Morning Movers: Capri Holdings jumps following sale of Versace to Prada
PremiumThe Fly
Morning Movers: Capri Holdings jumps following sale of Versace to Prada
18d ago
X
ASX
Keros reviewing strategic alternatives, adopts shareholder rights plan
PremiumThe Fly
Keros reviewing strategic alternatives, adopts shareholder rights plan
18d ago
KROS
Keros Therapeutics price target lowered to $25 from $43 at Truist
PremiumThe Fly
Keros Therapeutics price target lowered to $25 from $43 at Truist
19d ago
KROS
Optimistic Buy Rating for Keros Therapeutics Driven by Promising Pipeline and Trial Results
PremiumRatingsOptimistic Buy Rating for Keros Therapeutics Driven by Promising Pipeline and Trial Results
26d ago
KROS
Promising Investment Opportunity: Keros Therapeutics’ KER-065 Shows Potential in Duchenne Muscular Dystrophy Treatment
Premium
Ratings
Promising Investment Opportunity: Keros Therapeutics’ KER-065 Shows Potential in Duchenne Muscular Dystrophy Treatment
27d ago
KROS
Cautious Hold Rating on KER-065 Amid Promising Biomarker Trends and Safety Concerns
Premium
Ratings
Cautious Hold Rating on KER-065 Amid Promising Biomarker Trends and Safety Concerns
27d ago
KROS
Mixed Signals for Keros Therapeutics: Promising Data and Safety Concerns Lead to Hold Rating
PremiumRatings
Mixed Signals for Keros Therapeutics: Promising Data and Safety Concerns Lead to Hold Rating
27d ago
KROS
Keros Therapeutics reports results from Phase 1 clinical trial of KER-065
PremiumThe Fly
Keros Therapeutics reports results from Phase 1 clinical trial of KER-065
28d ago
KROS
3 Best Stocks to Buy Now, 3/17/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 3/17/2025, According to Top Analysts
1M ago
MU
APP
Buy Rating for Keros Therapeutics: Promising Potential of KER-065 Amidst Investor Concerns
PremiumRatings
Buy Rating for Keros Therapeutics: Promising Potential of KER-065 Amidst Investor Concerns
1M ago
KROS
Keros Therapeutics CEO to Speak at Major Conferences
PremiumCompany AnnouncementsKeros Therapeutics CEO to Speak at Major Conferences
2M ago
8K
KROS
Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns
Premium
Ratings
Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns
2M ago
KROS
Keros Therapeutics Strengthens Financial Position Amid R&D Expansion
Premium
Company Announcements
Keros Therapeutics Strengthens Financial Position Amid R&D Expansion
2M ago
KROS
Keros Therapeutics reports Q4 EPS ($1.14) vs. ($1.34) last year
PremiumThe Fly
Keros Therapeutics reports Q4 EPS ($1.14) vs. ($1.34) last year
2M ago
KROS
Keros Therapeutics CEO to Speak at Biotech Conference
PremiumCompany Announcements
Keros Therapeutics CEO to Speak at Biotech Conference
3M ago
8K
KROS
Keros Therapeutics announces effectiveness of global agreement with Takeda
PremiumThe Fly
Keros Therapeutics announces effectiveness of global agreement with Takeda
3M ago
TAK
KROS
Keros Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
PremiumThe Fly
Keros Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
3M ago
KROS
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
3M ago
ANIX
ERNA
Keros Therapeutics downgraded at Wedbush after removing PAH, obesity programs
Premium
The Fly
Keros Therapeutics downgraded at Wedbush after removing PAH, obesity programs
3M ago
KROS
Keros Therapeutics downgraded to Neutral from Outperform at Wedbush
Premium
The Fly
Keros Therapeutics downgraded to Neutral from Outperform at Wedbush
3M ago
KROS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >